The myeloma patient outcome scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma
No Thumbnail Available
Authors
Davies, Joanna M.
Osborne, Thomas R.
Edmonds, Polly M.
Schey, Steve A.
Devereux, Steve
Higginson, Irene J.
Ramsenthaler, Christina
Check for full-text access
Issue Date
2017
Type
Article
Language
Keywords
Alternative Title
Abstract
OBJECTIVES: The development of novel agents and an ageing population has led to an increasing number of patients with follicular lymphoma (FL) living longer with their disease. Health-related quality of life (HRQOL) is a priority for patients and should guide clinical decisions. The Myeloma Patient Outcome Scale (MyPOS), originally developed for myeloma, was validated in a cross-sectional survey recruiting 124 FL patients. METHODS: Content and construct validity, structural validity using confirmatory factor analyses, reliability and acceptability were evaluated. RESULTS: Three subscales were indicated: symptoms and function, emotional response, and healthcare support. MyPOS symptom and function scores were higher (worse) in participants with poorer ECOG performance status (F=26.2, P<.000) and discriminated between patients on and off treatment. Good convergent and discriminant validity in comparison to the EORTC-QLQ-C30 and FACT-Lym were demonstrated. Internal consistency was good; α coefficient 0.70-0.95 for the total MyPOS score and subscales. CONCLUSION: The MyPOS is valid, reliable and acceptable, and can be used to support clinical care of FL patients. This is the first measurement tool developed specially for use in clinical practice that has been validated for use in people with FL. Further longitudinal validation is now required to support its use in outcome measurement.
Description
Citation
Publisher
License
Journal
European Journal of Haematology
Volume
98
Issue
5